Collegium Pharmaceutical (COLL) Cost of Revenue (2016 - 2026)

Collegium Pharmaceutical's Cost of Revenue history runs 11 years deep, the most recent figure standing at $20.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 16.66% year-over-year to $20.8 million; the TTM figure through Mar 2026 stood at $146.7 million (up 8.2% YoY), while the FY2025 annual figure was $3.1 million, down 96.56% from the prior year.
• Cost of Revenue was $20.8 million for Q1 2026 at Collegium Pharmaceutical, down from $21.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $79.8 million in Q4 2022 to a low of $20.0 million in Q2 2024.
• Historically, Cost of Revenue has averaged $40.2 million across 5 years, with a median of $30.6 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Cost of Revenue tumbled 74.19% in 2023, then jumped 298.98% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $79.8 million in 2022, then sank by 74.19% to $20.6 million in 2023, then soared by 36.84% to $28.2 million in 2024, then decreased by 23.38% to $21.6 million in 2025, then dropped by 3.69% to $20.8 million in 2026.
• The last three Cost of Revenue figures came in at $20.8 million (Q1 2026), $21.6 million (Q4 2025), and $24.7 million (Q3 2025), per Business Quant data.